Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients

Author(s): Giuseppe Barbaro, Edward C. Klatt

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 18 , 2003

Become EABM
Become Reviewer
Call for Editor


Highly active antiretroviral therapy (HAART) has prolonged many patients lives, but many cardiac sequelae of HIV are not affected by HAART and continue to develop even with treatment. In addition, HAART itself causes in a high proportion of patients a metabolic syndrome, characterized by lipodystrophy / lipoatrophy, dyslipidemia and insulin resistance that may be associated with an increase in peripheral artery and coronary artery diseases. Careful cardiovascular evaluation in the course of HIV disease can identify cardiac complications early enough to treat. All HIV-infected patients who are either candidates to antiretroviral therapy or who are already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk with the available guidelines and the interactions between antiretrovirals and drugs commonly used to treat cardiovascular disease.

Keywords: human immunodeficiency virus, acquired immunodeficiency syndrome, highly active antiretroviral therapy, cardiovascular disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [1475 - 1481]
Pages: 7
DOI: 10.2174/1381612033454711
Price: $65

Article Metrics

PDF: 5